Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 164

Results For "NDA"

4483 News Found

Davaindia accelerates expansion with 1,165 operational stores
News | October 08, 2024

Davaindia accelerates expansion with 1,165 operational stores

Strategic focus on COCO-model with a nationwide reach of 501 stores


Lupin and Scope sign agreement for commercialization of Optase in Mexico
News | October 08, 2024

Lupin and Scope sign agreement for commercialization of Optase in Mexico

The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions


Calquence granted priority review in US for patients with untreated mantle cell lymphoma
Drug Approval | October 06, 2024

Calquence granted priority review in US for patients with untreated mantle cell lymphoma

Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy


AIIMS, New organises conference on ‘Advancing Oral Health in India’
Healthcare | October 06, 2024

AIIMS, New organises conference on ‘Advancing Oral Health in India’

Poor oral health (periodontal disease) impacts nearly 51% of Indians


Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility
News | October 04, 2024

Biocon Biologics refinances US$ 1.1 billion debt through USD bonds, new syndicated facility

US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years


Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
Drug Approval | October 04, 2024

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

This is used to treat central diabetes insipidus and bedwetting


Piramal Pharma releases Sustainability Report FY 2023-24
News | October 04, 2024

Piramal Pharma releases Sustainability Report FY 2023-24

The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence


Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)
Drug Approval | October 04, 2024

Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)

Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander


Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria
Digitisation | October 03, 2024

Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria

Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules


Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets
Drug Approval | October 03, 2024

Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets

Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures